A transaction-underwriting guide to fertility clinic M&A, including IVF cycle volume, embryology-lab capacity, patient acquisition and referral channels, physician continuity, payer and cash-pay mix, normalized EBITDA, strategic and private equity buyer demand, clinical and data diligence, financing, transaction structure, and seller proceeds.
A transaction-focused guide to home care agency valuation multiples, connecting operating evidence, buyer underwriting, transaction risk, and seller outcomes.
A transaction-focused guide to non-medical home care M&A, connecting operating evidence, buyer underwriting, transaction risk, and seller outcomes.
A transaction-underwriting guide to healthcare software M&A, including recurring revenue, retention, workflow embedment, implementation complexity, regulated end markets, interoperability, cybersecurity, product economics, valuation, structure, integration, capital alternatives, and seller proceeds.
A buyer-underwriting guide to the healthcare software acquirer landscape, including strategic software consolidators, healthcare IT platforms, sponsor-backed buyers, private equity, payer and provider technology companies, data and AI platforms, buyer-fit criteria, financing, diligence, integration, offer structure, and seller proceeds.
A seller-focused guide to selling a medspa, including exit planning, valuation preparation, buyer selection, medical and regulatory diligence, provider retention, confidentiality, LOI comparison, transaction structure, transition planning, and seller proceeds.
A buyer-focused guide to medspa acquirers, including strategic buyers, private equity sponsors, sponsor-backed platforms, adjacent healthcare acquirers, buyer-fit logic, diligence priorities, offer structure, integration, and seller proceeds.
This article explains how private equity buyers really underwrite a company in a live sale process, including how they think about normalized EBITDA, leverage capacity, downside protection, deal structure, and the gap between headline valuation and seller proceeds.
Private equity firms value companies by underwriting sustainable cash flow, growth durability, leverage capacity, and exit economics rather than relying on a headline multiple alone. This article explains how sponsors move from normalized EBITDA to enterprise value, equity value, and actual seller proceeds in a live M&A process.
Rollover equity in M&A allows sellers to reinvest part of their proceeds into the post-closing business instead of taking all consideration in cash at closing. This guide explains how rollover equity works, why private equity buyers require it, how it affects cash at closing, what “second bite of the apple” really means, and what sellers should negotiate before agreeing to roll.